Ingenious eBrain: Next Generation Technologies- Nucleic Acid Delivery System

Recent Advances and Approach Towards Nucleic Acid Delivery System RNAi therapeutics is now started taking momentum after successful clinical trials for different siRNAbased therapies, primarily for neural disorders and cancers. Their specificities in terms of posttranscriptional gene silencing have already been well established and many small and big players are engaged in designing and patenting novel RNAi sequences. Designing specific sequences for specific disease or disorders does not complete the invention, but it does also require maneuvering specific delivery agents for targeted delivery. Lipid-based delivery agents are primarily used for delivering different RNAi molecules, but other chemical agents such as peptides, DAEA-dextran etc. and biological agents such as viral particles have also been tried and tested. Download free sample: http://www.iebrain.com/reports/healthcare-pharmaceuticals/nucleic-aciddelivery-system/ Table of Contents: 1. Technology Overview 2. Technology Insights 3. Geographical distribution 4. Partnership / Collaboration / Licensing 5. Nucleic acid delivery â&#x20AC;&#x201C; Market overview 6. Nucleic acid delivery: Market Determinants 7. Nucleic acid delivery: Opportunity Vs. Restraints 8. Nucleic acid delivery: Strategic Analysis SWOT & PEST 9. Nucleic acid delivery: Market Development 10. Nucleic acid delivery: Recent advancements and future trend Click here for more insights: Reports About Us: At Ingenious eBrain, we believe that humans assisted with machine intelligence can deliver unparalleled results. Our proprietary in-house tools use the power of AI to deliver the most reliable results in half the time used by traditional methods. The AI assisted workflow allows cost-efficient decision making for even the most challenging problems. Contact Us @ Email Id: services@iebrain.com Contact No: +13474802054

Turn static files into dynamic content formats.

Create a flipbook

Ingenious eBrain: Next Generation Technologies- Nucleic Acid Delivery System

Published on Jun 11, 2018

Ingenious e-Brain Solutions

RNAi therapeutics is now started taking momentum after successful clinical trials for different siRNA-based therapies, primarily for neural disorders and cancers. Their specificities in terms of post-transcriptional gene silencing have already been well established and many small and big players are engaged in designing and patenting novel RNAi sequences. Designing specific sequences for specific disease or disorders does not complete the invention, but it does also require maneuvering specific delivery agents for targeted delivery. Lipid-based delivery agents are primarily used for delivering different RNAi molecules, but other chemical agents such as peptides, DAEA-dextran etc. and biological agents such as viral particles have also been tried and tested.